- |||||||||| sildenafil / Generic mfg., dihydroergotamine mesylate injection / Generic mfg.
Journal: Inhibitory Effect of a Microecological Preparation on Azoxymethane/Dextran Sodium Sulfate-Induced Inflammatory Colorectal Cancer in Mice. (Pubmed Central) - Nov 14, 2020
Integrated analysis of 16s rRNA and metabolomics data showed that there were 19 functional relationship pairs, including 8 altered microbiota, such as Ruminiclostridium and Prevotellaceae_UCG_001, and 16 disturbed metabolites between the JK5G and model groups. This study revealed that JK5G treatment was involved in the growth of colorectal cancer, which may be associated with the role of JK5G in improving the nutritional status of mice and regulating the tumor microenvironment by regulating the changes of intestinal microbiota and metabolite bands on different pathways.
- |||||||||| ketamine / Generic mfg., dihydroergotamine mesylate injection / Generic mfg.
Clinical, Review, Journal: Emergency Department and Inpatient Management of Headache in Adults. (Pubmed Central) - Oct 28, 2020
Other therapies (e.g., ketamine and lidocaine) are used with limited or inconsistent evidence...This article details red flags to review in the workup of headache presentation in the ED and provides a step-wise approach to ED and inpatient management. However, more studies are needed to better optimize care.
- |||||||||| ketamine / Generic mfg.
[VIRTUAL] Ketamine For Refractory Chronic Migraine: A Pilot Study () - Oct 17, 2020 - Abstract #ASA2020ASA_419;
2,3 Our primary objective was to determine if the improvement in pain after ketamine was greater than the improvement after lidocaine/dihydroergotamine (DHE)...All patients received transdermal clonidine and lorazepam prn for adverse effects (AEs)...Discussion Ketamine was well tolerated and improved short-term pain in RCM patients better than the combination of lidocaine/DHE but the clinical significance is uncertain. Mechanistic and sustained-benefit studies should be performed.
- |||||||||| dihydroergotamine mesylate injection / Generic mfg.
FDA event, Journal: In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors. (Pubmed Central) - Aug 26, 2020
Interestingly, the anti-migraine drugs such as ergotamine and its derivative, dihydroergotamine were found to bind to all the three target enzymes within the Cys-His catalytic dyad cleft with lower binding energies as compared to the control inhibitors (α-ketoamide 13b, SG85 and GC813) and the molecules are held within the pocket through a good number of hydrogen bonds and hydrophobic interactions. Hence both these lead molecules can be further taken for wet-lab experimentation studies before repurposing them as anti-coronaviral drug candidates.
- |||||||||| dihydroergotamine mesylate injection / Generic mfg.
Journal: Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk. (Pubmed Central) - Jul 16, 2020
Triptans and dihydroergotamine (DHE) are contraindicated in patients with hemiplegic and basilar migraine based on theories of migraine pathophysiology from the 1930s...This recognition has led the International Headache Society to rename basilar-type migraine to migraine with brainstem aura. The following discussion reviews current literature with respect to migraine as a neuronal disorder, as well as the published data on the safety of triptans, DHE, Ditans (a novel class of 5-HT receptor agonists), CGRP antibodies, and Gepants.
- |||||||||| dihydroergotamine mesylate injection / Generic mfg.
[VIRTUAL] The Efficacy of Dihydroergotamine versus Emerging Acute Migraine Medications () - Jul 15, 2020 - Abstract #AHS2020AHS_272;
However, DHE use has been limited by route of administration and/or performance of approved dosage forms. Newer investigational products, such as STS101 (intranasal DHE powder), that demonstrate Cmax and drug exposure comparable to or greater than MAP0004, may overcome these limitations and provide more consistent and reliable clinical performance.
- |||||||||| dihydroergotamine mesylate injection / Generic mfg.
[VIRTUAL] Safety of Dihydroergotamine for Acute Migraine Treatment: Reality vs Perception () - Jul 15, 2020 - Abstract #AHS2020AHS_257;
In the US, DHE has been used since 1945 for the acute treatment of migraine headache in a parenteral formulation (DHE45) and since 1997 as an intranasal liquid spray (Migranal). DHE is safe and well tolerated for the acute treatment of migraine in the appropriate patient population.
- |||||||||| dihydroergotamine mesylate injection / Generic mfg., chlorpromazine / Generic mfg.
[VIRTUAL] Efficacy of Inpatient Infusions for Patients with Chronic Migraine and History of Head Trauma () - Jul 15, 2020 - Abstract #AHS2020AHS_139;
Treatment outcomes are comparable to the general chronic migraine population undergoing similar infusion admissions. Given promising outcomes on patient headache status with this small pilot study, studies to confirm this benefit in a larger cohort of chronic migraine patients with a history of head trauma are warranted.
- |||||||||| dihydroergotamine mesylate injection / Generic mfg.
[VIRTUAL] Does Dihydroergotamine Treat the “whole Migraine”? () - Jul 15, 2020 - Abstract #AHS2020AHS_123;
Moreover, the slow dissociation of DHE from target receptors is thought to sustain its anti-migraine effects therefore reducing headache recurrence rates and medication overuse headaches. Achieving dose-to-dose consistency and optimal plasma concentrations of DHE has been demonstrated to maximize therapeutic gain while providing safety and tolerability in addressing acute migraine.
- |||||||||| indomethacin / PLx Pharma Inc, Generic mfg., Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Bilateral Hemicrania Continua Presenting as New Daily Persistent Headache Responsive to Indomethacin () - Jul 15, 2020 - Abstract #AHS2020AHS_92;
This case presented as new daily persistent headache with a clearly identified day of onset of headache with lack of response to other therapies, similarly to what many clinicians report in treating patients with NDPH. This case illustrates that in patients presenting with what seems to be new daily persistent headache that have failed to respond to other interventions, a trial of indomethacin may be warranted, even if head pain is bilateral.
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Imperan (metoclopramide) / Generic mfg.
Clinical, Journal: Experiences of an outpatient infusion center with intravenous magnesium therapy for status migrainosus. (Pubmed Central) - May 15, 2020
For a subset of patients with status migrainosus, IV magnesium therapy results in clinically significant pain relief without the need for intramuscular pain medications. Therefore, IV magnesium may be useful as a cost-effective first-line parental therapy for status migrainosus, especially for patients who initially present with lower pain intensity.
- |||||||||| dihydroergotamine mesylate injection / Generic mfg.
Effect of Dihydroergotamine Infusion Rate on Inpatient Headache Treatment Outcomes () - Jan 21, 2020 - Abstract #AAN2020AAN_2411;
Prolongation of infusion time to manage cramping led to improvement of side effects, but did not interfere with efficacy of the treatment. Future randomized studies need to be done to see if IV DHE over 90-120 min can proactively reduce side effects in all patients undergoing IV DHE admission without decrease in efficacy.
- |||||||||| dihydroergotamine mesylate injection / generics, chlorpromazine / generics
Review, Journal: Intravenous lidocaine for acute pain: a systematic review. (Pubmed Central) - Sep 12, 2019
Due to the inconsistency in dosing, length of administration, and lack of serum monitoring, the absolute safety of IV lidocaine for acute pain is unknown. Larger, prospective studies are needed before the routine use of IV lidocaine can be recommended for all types of acute pain.
- |||||||||| dihydroergotamine mesylate injection / generics
Preclinical, Journal: Development and In Vitro/In Vivo Evaluation of Dihydroergotamine Mesylate Loaded Maltodextrin-Pullulan Sublingual Films. (Pubmed Central) - Sep 4, 2019
The application of optimum formulation to rabbits showed that bioavailability of formulation is about 23.35% with a t 20 min. Due to this fast onset of action and higher bioavailability than oral administration, it is suggested that the polymer combinations of pullulan and maltodextrin formed successful films and were considered as alternative dosage form for DHE in migraine therapy.
- |||||||||| dihydroergotamine mesylate injection / generics
Journal: Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. (Pubmed Central) - May 31, 2019
We show that DHE induces NR4A expression via recruitment of the super elongation complex to enable elongation of NR4A promoter paused RNA polymerase II. Finally, DHE exhibits AML selective NR4A-dependent anti-leukemic activity in cytogenetically distinct human AML cells in vitro and delays AML progression in mice revealing its potential as a novel therapeutic agent in AML.
- |||||||||| dihydroergotamine mesylate injection / generics
Journal: Acute Migraine Headache: Treatment Strategies. (Pubmed Central) - May 29, 2019
The pharmacologic properties, potential adverse effects, cost, and routes of administration vary widely, allowing therapy to be individualized based on the pattern and severity of attacks. Several treatment principles, including taking medication early in an attack and using a stratified treatment approach, can help ensure that migraine treatment is cost-effective.
- |||||||||| paracetamol / Generic mfg.
Trial completion date, Trial suspension, Trial primary completion date, Head-to-Head: Cefalium (clinicaltrials.gov) - Apr 10, 2019
P3, N=336, Suspended,
This approach has the potential to prolonged the benefit of IV DHE and prevent relapse in to status migrainosus. Trial completion date: Jun 2020 --> Jun 2021 | Not yet recruiting --> Suspended | Trial primary completion date: Apr 2020 --> Apr 2021
- |||||||||| paracetamol / Generic mfg.
Trial completion date, Trial primary completion date, Head-to-Head: Cefalium (clinicaltrials.gov) - Apr 12, 2018
P3, N=336, Not yet recruiting,
Trial completion date: Jun 2020 --> Jun 2021 | Not yet recruiting --> Suspended | Trial primary completion date: Apr 2020 --> Apr 2021 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Apr 2019 --> Apr 2020
- |||||||||| paracetamol / Generic mfg.
Trial initiation date, Trial primary completion date, Head-to-Head: Cefalium (clinicaltrials.gov) - Feb 15, 2017
P3, N=336, Not yet recruiting,
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Apr 2019 --> Apr 2020 Initiation date: Jan 2017 --> Apr 2018 | Trial primary completion date: Jan 2018 --> Apr 2019
- |||||||||| paracetamol / Generic mfg.
Trial primary completion date, Head-to-Head: Cefalium (clinicaltrials.gov) - Apr 28, 2016
P3, N=336, Not yet recruiting,
Initiation date: Jan 2017 --> Apr 2018 | Trial primary completion date: Jan 2018 --> Apr 2019 Trial primary completion date: Aug 2017 --> Jan 2018
- |||||||||| paracetamol / Generic mfg.
Trial initiation date, Trial primary completion date, Head-to-Head: Cefalium (clinicaltrials.gov) - Mar 8, 2016
P3, N=336, Not yet recruiting,
Trial primary completion date: Aug 2017 --> Jan 2018 Initiation date: Oct 2015 --> Feb 2017 | Trial primary completion date: Aug 2016 --> Aug 2017
- |||||||||| paracetamol / Generic mfg.
New P3 trial, Head-to-Head: Cefalium (clinicaltrials.gov) - Oct 22, 2015
P3, N=336, Not yet recruiting,
|
